Preparing Surrogates of Dementia Patients Through an Advance Care Planning Intervention

Sponsor
The University of Hong Kong (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT06152120
Collaborator
(none)
120
1
2
17.5
6.8

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to evaluate the effects of a nurse-facilitated post-discharge advance care planning intervention with family surrogates of dementia patients on outcomes that reflect the preparedness of surrogates in decision-making.

The main question it aims to answer is, whether the ACP intervention as compared with usual care will increase family surrogates' self-efficacy in surrogate decision-making and reduce their levels of distress, and increase patient comfort and reduce acute healthcare utilization at 2 and 6 months.

Participants will be randomized to ACP intervention vs. usual care.

  1. patients of the Intervention group will be assessed on palliative care needs, and surrogates of the Intervention group will participate in 2-3 nurse-led ACP consultations;

  2. surrogates of both intervention and control groups will complete 3 surveys at different time points during their participation of the study.

Researchers will compare the intervention group and control group to see any differences in:
  1. surrogate preparedness for decision-making,

  2. distress of surrogate and satisfaction with the care of loved one with dementia at the end-of-life,

  3. enrolment in Community Geriatric Assessment Team end-of-life care program,

  4. advanced care program documentation in medical record,

  5. patient comfort at end-of-life,

  6. hospitalizations in the last 6 months of life.

Condition or Disease Intervention/Treatment Phase
  • Other: Nurse-facilitated advance care planning intervention
N/A

Detailed Description

In order to test the ACP interventions that aim to engage surrogates' participation in ACP and improve their preparedness for decision-making rather than on documentation of advance care plans alone, our team has developed a pilot structured, nurse-facilitated post-discharge ACP intervention with the aim to improve surrogates' preparedness for in-the-moment decision-making.

It does so by incorporating best practices for ACP communication, drawing from prior work of the research team and existing literature, combined with a focus on developing surrogates' self-efficacy for decision-making guided by Bandura's Social Cognitive Theory.

This application aims to test the intervention's effects on surrogate outcomes (decision-making self-efficacy and distress), patient outcomes (patient comfort and healthcare utilization), as well as process outcomes (ACP documentation, end-of-life care discussions between family members, and enrolment in end-of-life care programs).

The research hypotheses to be tested are as follows: We will test whether the ACP intervention as compared with usual care will increase family surrogates' self-efficacy in surrogate decision-making and reduce their levels of distress, and increase patient comfort and reduce acute healthcare utilization at 2 and 6 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
We will use a sequential mixed-methods approach including a pilot randomized controlled trial using a quantitative study to evaluate the effects of a structured nurse-facilitated ACP intervention and a qualitative study to explore the perceptions of the family surrogates and the ACP nurse facilitator on the ACP intervention. Each patient-family dyad will be randomized in a 1:1 ratio to ACP intervention vs. usual care before the baseline interview.We will use a sequential mixed-methods approach including a pilot randomized controlled trial using a quantitative study to evaluate the effects of a structured nurse-facilitated ACP intervention and a qualitative study to explore the perceptions of the family surrogates and the ACP nurse facilitator on the ACP intervention. Each patient-family dyad will be randomized in a 1:1 ratio to ACP intervention vs. usual care before the baseline interview.
Masking:
Single (Outcomes Assessor)
Masking Description:
Research staff will be blinded to the study arm when collecting data from family surrogates by telephone at follow up time-points. The study biostatistician will also be blinded to the allocation of the study arm.
Primary Purpose:
Health Services Research
Official Title:
Preparing Surrogates of Dementia Patients for In-the-moment Decision Making Through a Structured Advance Care Planning Intervention: A Mixed-methods Pilot Study
Actual Study Start Date :
Jun 15, 2023
Anticipated Primary Completion Date :
Nov 30, 2024
Anticipated Study Completion Date :
Nov 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: ACP Intervention arm

The group which will participate in nurse-facilitated advance care planning intervention.

Other: Nurse-facilitated advance care planning intervention
The intervention consists of two components: Component 1. Palliative care needs assessment - The research nurse will conduct a palliative care needs assessment and also review related information from the medical chart, which will enable the nurse to provide tailored information on the patient's illness, prognosis, and palliative care needs during subsequent ACP consultations. Component 2: Structured nurse-facilitated ACP consultations - The research nurse will conduct post-discharge ACP consultations with the family surrogate, with content that includes: assess readiness for discussions, introduce video decision aides to provide related ACP information and share examples of family surrogates with similar experiences.

No Intervention: Usual care arm

The group which will not participate in nurse-facilitated advance care planning intervention.

Outcome Measures

Primary Outcome Measures

  1. Modified Family Member Decision-Making Self-efficacy Scale (FDMSE) - Chinese version [Baseline, 2-month, 6-month]

    This is a modified 17-item version of the FDMSE, a valid and reliable scale that quantifies a family member's confidence (0-100, where 100 = greatest self-efficacy) in end-of-life care decision-making for a loved one.

  2. Family Distress in Advanced Dementia Scale (FDAD) - Chinese version [Baseline, 2-month, 6-month]

    The FDAD is a validated 21-item scale rated on a 1-5 scale, with higher scores indicating greater family distress.

Secondary Outcome Measures

  1. End-of-life care discussions with other family members [Baseline, 2-month, 6-month]

    The number of conversations which the surrogate has with other family members regarding end-of-life care decisions for the patient with advanced dementia.

  2. Documentation of ACP discussions with medical providers [Baseline, 2-month, 6-month]

    Information on the date of ACP discussion, type of clinician(s) involved, and care decisions in the Hospital Authority Clinical Management System.

  3. Enrolment in Community Geriatric Assessment Team End-of-Life (CGAT EOL) care program [2-month, 6-month]

    Occurrence and date of new enrolment in the CGAT EOL care program in the Hospital Authority Clinical Management System.

  4. Comfort Assessment in Dying with Dementia (CAD-EOLD) [2-month, 6-month]

    Measure of common symptoms and conditions to assess comfort of advanced dementia patients across 4 domains: Physical Distress, Emotional Distress, Well Being, and Dying Symptoms.

  5. Unplanned hospital admissions and hospitalization days [2-month, 6-month]

    The number of unplanned hospital admissions and hospitalization days in public and private hospitals.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria for the Patient-Surrogate dyad:
  • Patient (a) at or above the age of 60 years old, (b) with diagnosis of dementia based on DSM-5 Criteria for Major Neurocognitive Disorder and Stage 6d or above on the Global Deterioration Scale (GDS), (c) residing in a residential care home that is participating in Hospital Authority Enhanced Community Geriatric Assessment Team End-of-Life (CGAT EOL) Care program and (d) has an eligible family decision-maker.

  • Surrogate (a) at or above the age of 18 years old, (b) identified as the patient's next of kin or legal guardian who is the 'key decision maker' in hospital records, and (c) able to provide informed consent for him/herself and the patient.

Exclusion Criteria:
  • Patient with (i) prior completed advance directive, (ii) prior decision regarding feeding tube insertion due to feeding problems was made in conjunction with a healthcare provider, (iii) currently enrolled in an end-of-life care program or palliative care service, or (iv) with family members who lack consensus on the primary family surrogate decision-maker.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The University of Hong Kong Hong Kong Hong Kong

Sponsors and Collaborators

  • The University of Hong Kong

Investigators

  • Principal Investigator: Jacqueline Yuen, Dr, The University of Hong Kong

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
YUEN Jacqueline Kwan Yuk, Clinical Assistant Professor, The University of Hong Kong
ClinicalTrials.gov Identifier:
NCT06152120
Other Study ID Numbers:
  • 20212481
First Posted:
Nov 30, 2023
Last Update Posted:
Nov 30, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by YUEN Jacqueline Kwan Yuk, Clinical Assistant Professor, The University of Hong Kong
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 30, 2023